XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors
Metastatic NSCLC - Non-Small Cell Lung Cancer · Advanced Solid Tumor
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 180 (planned)
- Started
- Oct 21, 2026
- Main results expected
- Nov 2029
- Fully finished
- Nov 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of Dose Limiting Toxicities (DLTs) in Part 1A
Measured over: Cycle 1 Day 1 up to just prior to the second dose of study drug (approximately 21 days)
Incidence of treatment-emergent adverse events (Phase 1 and Phase 2)
Measured over: Up to Safety Follow Up Period (90 [+7] days after the last dose)
Incidence of serious adverse events (Phase 1 and Phase 2)
Measured over: Up to Safety Follow Up Period (90 [+7] days after the last dose)
Incidence of significant change from baseline in clinical laboratory values (Phase 1 and Phase 2)
Measured over: Up to Safety Follow Up Period (90 [+7] days after the last dose)
Investigator-assessed objective response rate (ORR) per RECIST v1.1 (Phase 2)
Measured over: Up to Safety Follow Up Period (90 [+7] days after the last dose)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07688577 · record last updated 2026-11-04 · checked 2026-11-09 15:47 UTC